Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis
Sustained disease control is an important consideration in managing chronic diseases with fluctuating symptoms such as gMG. Study results showed that nipocalimab provided a comparable onset of action and consistent and sustained disease control that was numerically or statistically significantly greater (depending on ITC method) when compared with the symptom-based cyclic FcRn blockers efgartigimod and rozanolixizumab.
Authors
- Mahmoud Hashim (ORCID: https://orcid.org/0000-0002-5775-9590)
- Christopher Drudge (ORCID: https://orcid.org/0000-0001-9721-3069)
- Suzy Van Sanden
- Brian Hutton (ORCID: https://orcid.org/0000-0001-5662-8647)
- Antoine C. El Khoury
- Kavita Gandhi
- Mi Jun Keng
- Sumeet Singh
- Rafal Slowik
- Nils Erik Gilhus
- Saiju Jacob
- Sindhu Ramchandren
Institutions
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Johnson & Johnson (United States) (US)
- Ottawa Hospital (CA)
- Haukeland University Hospital (NO)
- EVERSANA (Canada) (CA)
- Ottawa Hospital Research Institute (CA)
- University of Bergen (NO)
- University of Birmingham (GB)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s12325-026-03543-1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00